ERBB2 and breast cancer: A review of medical records of 171 patients with locally advanced or metastatic HR+/HER2- breast cancer who received fulvestrant treatment showed that 66.9% of patients experienced drug-related adverse reactions, with severe adverse reactions accounting for 8.6% of cases8.